BIM
MYGN icon

Bogle Investment Management’s Myriad Genetics MYGN Stock Holding History

Bogle Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-41,099
Closed -$1.21M – 326
2018
Q1 		$1.21M Sell
41,099
-297,093
-88% -$10.1M 0.09% 193
2017
Q4 		$11.6M Buy
+338,192
New +$11.4M 0.85% 46
2017
Q1 		– Sell
-84,914
Closed -$1.42M – 356
2016
Q4 		$1.42M Sell
84,914
-444,055
-84% -$8.03M 0.1% 215
2016
Q3 		$10.9M Buy
+528,969
New +$13.4M 0.78% 43
2013
Q4 		– Sell
-334,165
Closed -$7.85M – 341
2013
Q3 		$7.85M Buy
334,165
+54,407
+19% +$1.55M 0.8% 34
2013
Q2 		$7.52M Buy
+279,758
New +$8.11M 0.92% 20

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bogle Investment Management's MYGN Position: Q2 2018 in Review

Bogle Investment Management sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 41,099 shares — an estimated $1.21M sold.

Bogle Investment Management first reported a position in MYGN in Q2 2013 and held it in 6 quarters. The position peaked at $11.6M in Q4 2017. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

  • Bogle Investment Management reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
  • Bogle Investment Management sold 41,099 Myriad Genetics shares in Q2 2018, an estimated $1.21M.
  • Bogle Investment Management first reported a position in Myriad Genetics in Q2 2013 and held it in 6 quarters.
  • Bogle Investment Management's Myriad Genetics position peaked at $11.6M in Q4 2017.
  • 258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on Bogle Investment Management's 13F filing for Q2 2018, filed 13 Aug 2018.